Hypothermia not Supported as a Therapeutic Option for Traumatic Brain Injury in Recent Randomized Trial

Abstract

Traumatic brain injury (TBI) is a leading cause of permanent disability in people younger than 40 years of age. An increase in intracranial pressure (ICP) during hospitalization for a TBI has been associated with poor long-term neurologic outcomes. On the basis of encouraging research, hypothermia has been embraced by some centers as an innovative way to treat high ICP. More recent trials, however, have hinted that therapeutic hypothermia might contribute to poor neurologic outcomes. In an attempt to define the role of hypothermia in TBI, the Eurotherm 3235 Trial collaborators conducted a randomized controlled trial, which was published October 7, 2015 in the New England Journal of Medicine. The inclusion criteria included patients with closed head injury who sustained an ICP >20 mm Hg for >5 minutes. For the purpose of creating a framework for study analysis, treatments for TBI were divided into stage 1, 2, and 3 therapies (Table 1). Eligible patients were randomized to an experimental arm, hypothermia (32 C 35 C) in addition to best management practice, and a control arm that consisted of best management practices alone. Statistical analysis was performed using ordinal logistic regression to compare the Extended Glasgow Outcome Scale scores between the hypothermia and control groups at 6 months. Only 25.7% of patients from the hypothermia group (49/191) had favorable outcomes at